title: Pharmacokinetic and pharmacodynamic comparisons of twice daily and four times daily formulations of procainamide in patients with frequent ventricular premature depolarization.
abstract: A study was conducted to evaluate the pharmacokinetics of procainamide and its active metabolite, N-acetylprocainamide (NAPA), as a function of dose and formulation and to characterize the relationship between ventricular premature depolarization (VPD) rate and plasma concentrations of procainamide and NAPA. A subset of patients (n = 43) with frequent VPD who were enrolled in a double-blind, multicenter, activity trial were assigned in randomized fashion to receive 1 of 4 dose levels (placebo or 1,000, 2,000, or 4,000 mg/day procainamide) and to receive Procanbid (Parke-Davis) tablets every 12 hours or Procan SR (Parke-Davis) tablets every 6 hours during the first week of a blinded crossover phase. Patients crossed over to the alternative formulation after one week. Maximum and steady-state average concentrations of procainamide and NAPA after administration of Procanbid tablets were equivalent to those after administration of an equivalent daily dose of Procan SR tablets. Corresponding trough concentrations of procainamide were lower after administration of Procanbid tablets than after administration of Procan SR tablets. Both formulations produced disproportionate increases in procainamide concentrations with increasing dose; concentrations of NAPA increased in proportion to dose. Assessment of the relationship between VPD rate and drug concentration in plasma indicated no substantive difference between the two formulations. It was concluded that administration of Procanbid tablets every 12 hours is essentially equivalent to administration of procainamide extended-release tablets (Procan SR) every 6 hours with respect to pharmacokinetics of procainamide and NAPA and to VPD suppression.
authors.affiliation: Department of Pharmacokinetics/Drug Metabolism, Parke-Davis Pharmaceutical Research, Ann Arbor, MI 48105, USA.
authors.forename: B B
authors.initials: BB
authors.lastname: Yang
authors.forename: R B
authors.initials: RB
authors.lastname: Abel
authors.forename: A C
authors.initials: AC
authors.lastname: Uprichard
authors.forename: J A
authors.initials: JA
authors.lastname: Smithers
authors.forename: S T
authors.initials: ST
authors.lastname: Forgue
mesh_terms: D000120:Acecainide / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000378:metabolism; D002626:Chemistry, Pharmaceutical; D018592:Cross-Over Studies; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D011342:Procainamide / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D013607:Tablets; D018879:Ventricular Premature Complexes
chemical_list: D000889:Anti-Arrhythmia Agents; D003692:Delayed-Action Preparations; D013607:Tablets; D000120:Acecainide; D011342:Procainamide